American Journal of Kidney Diseases

Serum Phosphorus and Mortality in the Third National Health and Nutrition Examination Survey (NHANES III): Effect Modification by Fasting


      Serum phosphorus levels have been associated with mortality in some but not all studies. Because dietary intake prior to measurement can affect serum phosphorus levels, we hypothesized that the association between serum phosphorus level and mortality is strongest in those who have fasted longer.

      Study Design

      Prospective cohort study.

      Setting & Participants

      Nationally representative sample of 12,984 participants 20 years or older in the Third National Health and Nutrition Examination Survey (1988-1994).


      Serum phosphorus level, fasting duration (dichotomized as ≥12 or <12 hours).


      All-cause and cardiovascular mortality determined by death certificate data from the National Death Index.


      Serum phosphorus measured in a central laboratory and fasting duration recorded as time since food or drink other than water was consumed.


      Individuals fasting 12 or more hours had lower serum phosphorus levels than those fasting less than 12 hours (3.34 vs 3.55 mg/dL; P < 0.001) and higher correlation with repeat measurement (0.66 vs 0.53; P = 0.002). In multivariable-adjusted Cox regression models, the highest quartile of serum phosphorus was associated with increased mortality in participants fasting 12 or more hours (adjusted HR, 1.74; 95% CI, 1.38-2.20; reference, lowest quartile) but not in participants fasting less than 12 hours (adjusted HR, 1.08; 95% CI, 0.89-1.32; P for interaction = 0.002). Relationships were consistent using 8 hours as the fasting cutoff point or cardiovascular mortality as the outcome.


      Observational study, lack of fibroblast growth factor 23 or intact parathyroid hormone measurements.


      Fasting but not nonfasting serum phosphorus levels were associated with increased mortality. Risk prognostication based on serum phosphorus may be improved using fasting levels.

      Index Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Tonelli M.
        • Sacks F.
        • Pfeffer M.
        • Gao Z.
        • Curhan G.
        • Cholesterol And Recurrent Events Trial Investigators
        Relation between serum phosphate level and cardiovascular event rate in people with coronary disease.
        Circulation. 2005; 112: 2627-2633
        • Dhingra R.
        • Sullivan L.M.
        • Fox C.S.
        • et al.
        Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community.
        Arch Intern Med. 2007; 167: 879-885
        • Foley R.N.
        • Collins A.J.
        • Herzog C.A.
        • Ishani A.
        • Kalra P.A.
        Serum phosphorus levels associate with coronary atherosclerosis in young adults.
        J Am Soc Nephrol. 2009; 20: 397-404
        • Tuttle K.R.
        • Short R.A.
        Longitudinal relationships among coronary artery calcification, serum phosphorus, and kidney function.
        Clin J Am Soc Nephrol. 2009; 4: 1968-1973
        • Haut L.L.
        • Alfrey A.C.
        • Guggenheim S.
        • Buddington B.
        • Schrier N.
        Renal toxicity of phosphate in rats.
        Kidney Int. 1980; 17: 722-731
        • Shuto E.
        • Taketani Y.
        • Tanaka R.
        • et al.
        Dietary phosphorus acutely impairs endothelial function.
        J Am Soc Nephrol. 2009; 20: 1504-1512
        • Kestenbaum B.
        • Sampson J.N.
        • Rudser K.D.
        • et al.
        Serum phosphate levels and mortality risk among people with chronic kidney disease.
        J Am Soc Nephrol. 2005; 16: 520-528
        • Voormolen N.
        • Noordzij M.
        • Grootendorst D.C.
        • et al.
        High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients.
        Nephrol Dial Transplant. 2007; 22: 2909-2916
        • Kovesdy C.P.
        • Anderson J.E.
        • Kalantar-Zadeh K.
        Outcomes associated with serum phosphorus level in males with non-dialysis dependent chronic kidney disease.
        Clin Nephrol. 2010; 73: 268-275
        • Mehrotra R.
        • Peralta C.A.
        • Chen S.C.
        • et al.
        No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease.
        Kidney Int. 2013; 84: 989-997
        • Menon V.
        • Greene T.
        • Pereira A.A.
        • et al.
        Relationship of phosphorus and calcium-phosphorus product with mortality in CKD.
        Am J Kidney Dis. 2005; 46: 455-463
        • Portale A.A.
        • Halloran B.P.
        • Morris Jr., R.C.
        Dietary intake of phosphorus modulates the circadian rhythm in serum concentration of phosphorus. Implications for the renal production of 1,25-dihydroxyvitamin D.
        J Clin Invest. 1987; 80: 1147-1154
        • Jubiz W.
        • Canterbury J.M.
        • Reiss E.
        • Tyler F.H.
        Circadian rhythm in serum parathyroid hormone concentration in human subjects: correlation with serum calcium, phosphate, albumin, and growth hormone levels.
        J Clin Invest. 1972; 51: 2040-2046
        • Wills M.R.
        The effect of diurnal variation on total plasma calcium concentration in normal subjects.
        J Clin Pathol. 1970; 23: 772-777
      1. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Series 1: programs and collection procedures. Vital Health Stat 1. 1994;(32)(32):1-407.

        • Levey A.S.
        • Stevens L.A.
        • Schmid C.H.
        • et al.
        A new equation to estimate glomerular filtration rate.
        Ann Intern Med. 2009; 150: 604-612
      2. NHANES III linked mortality file. Centers for Disease Control and Prevention, Atlanta, GA2009 ([updated September 25; cited August 13, 2012]) (Accessed May 20, 2013)
      3. World Health Organization. International Statistical Classification of Diseases and Related Health Problems. 10th revision. (ICD-10-CM). Geneva, Switzerland: World Health Organization; 1992.

        • Fisher R.A.
        Frequency distribution of the values of the correlation coefficients in samples from an indefinitely large population.
        Biometrika. 1915; 10: 507-521
        • Polymeris A.D.
        • Doumouchtsis K.K.
        • Giagourta I.
        • Karga H.
        Effect of an oral glucose load on PTH, 250HD3, calcium, and phosphorus homeostasis in postmenopausal women.
        Endocr Res. 2011; 36: 45-52
        • Masarei J.R.
        The effect of 50 grams of glucose orally on a number of biochemical variables.
        Pathology. 1977; 9: 19-25
        • Bowe A.E.
        • Finnegan R.
        • Jan de Beur S.M.
        • et al.
        FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate.
        Biochem Biophys Res Commun. 2001; 284: 977-981
        • Wolf M.
        Update on fibroblast growth factor 23 in chronic kidney disease.
        Kidney Int. 2012; 82: 737-747
        • Faul C.
        • Amaral A.P.
        • Oskouei B.
        • et al.
        FGF23 induces left ventricular hypertrophy.
        J Clin Invest. 2011; 121: 4393-4408
        • Ix J.H.
        • Katz R.
        • Kestenbaum B.R.
        • et al.
        Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study).
        J Am Coll Cardiol. 2012; 60: 200-207
        • Gutierrez O.M.
        • Januzzi J.L.
        • Isakova T.
        • et al.
        Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.
        Circulation. 2009; 119: 2545-2552
        • Scialla J.J.
        • Astor B.C.
        • Isakova T.
        • Xie H.
        • Appel L.J.
        • Wolf M.
        Mineral metabolites and CKD progression in african americans.
        J Am Soc Nephrol. 2013; 24: 125-135
        • Abramowitz M.
        • Muntner P.
        • Coco M.
        • et al.
        Serum alkaline phosphatase and phosphate and risk of mortality and hospitalization.
        Clin J Am Soc Nephrol. 2010; 5: 1064-1071
        • Tonelli M.
        • Curhan G.
        • Pfeffer M.
        • et al.
        Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality.
        Circulation. 2009; 120: 1784-1792
        • Kovesdy C.P.
        • Ureche V.
        • Lu J.L.
        • Kalantar-Zadeh K.
        Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD.
        Nephrol Dial Transplant. 2010; 25: 3003-3011
        • Drechsler C.
        • Verduijn M.
        • Pilz S.
        • et al.
        Bone alkaline phosphatase and mortality in dialysis patients.
        Clin J Am Soc Nephrol. 2011; 6: 1752-1759
        • Iba K.
        • Takada J.
        • Yamashita T.
        The serum level of bone-specific alkaline phosphatase activity is associated with aortic calcification in osteoporosis patients.
        J Bone Miner Metab. 2004; 22: 594-596
        • Yamamoto K.T.
        • Robinson-Cohen C.
        • de Oliveira M.C.
        • et al.
        Dietary phosphorus is associated with greater left ventricular mass.
        Kidney Int. 2013; 83: 707-714
        • Chang A.R.
        • Lazo M.
        • Appel L.J.
        • Gutierrez O.M.
        • Grams M.E.
        High dietary phosphorus intake is associated with all-cause mortality: results from NHANES III.
        Am J Clin Nutr. 2014; 99: 320-327
        • Isakova T.
        • Gutierrez O.M.
        • Chang Y.
        • et al.
        Phosphorus binders and survival on hemodialysis.
        J Am Soc Nephrol. 2009; 20: 388-396
        • Chertow G.M.
        • Burke S.K.
        • Raggi P.
        • Treat to Goal Working Group
        Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.
        Kidney Int. 2002; 62: 245-252
        • Suki W.N.
        • Zabaneh R.
        • Cangiano J.L.
        • et al.
        Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients.
        Kidney Int. 2007; 72: 1130-1137
        • Di Iorio B.
        • Molony D.
        • Bell C.
        • et al.
        Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial.
        Am J Kidney Dis. 2013; 62: 771-778
        • Block G.A.
        • Wheeler D.C.
        • Persky M.S.
        • et al.
        Effects of phosphate binders in moderate CKD.
        J Am Soc Nephrol. 2012; 23: 1407-1415
        • Leon J.B.
        • Sullivan C.M.
        • Sehgal A.R.
        The prevalence of phosphorus-containing food additives in top-selling foods in grocery stores.
        J Ren Nutr. 2013; 23 (270.e2): 265
        • Calvo M.S.
        • Uribarri J.
        Contributions to total phosphorus intake: all sources considered.
        Semin Dial. 2013; 26: 54-61
        • de Boer I.H.
        • Rue T.C.
        • Kestenbaum B.
        Serum phosphorus concentrations in the Third National Health and Nutrition Examination Survey (NHANES III).
        Am J Kidney Dis. 2009; 53: 399-407
        • Kempson S.A.
        • Lotscher M.
        • Kaissling B.
        • Biber J.
        • Murer H.
        • Levi M.
        Parathyroid hormone action on phosphate transporter mRNA and protein in rat renal proximal tubules.
        Am J Physiol. 1995; 268: F784-F791
        • Kaplan R.A.
        • Haussler M.R.
        • Deftos L.J.
        • Bone H.
        • Pak C.Y.
        The role of 1 alpha, 25-dihydroxyvitamin D in the mediation of intestinal hyperabsorption of calcium in primary hyperparathyroidism and absorptive hypercalciuria.
        J Clin Invest. 1977; 59: 756-760
        • Berndt T.
        • Thomas L.F.
        • Craig T.A.
        • et al.
        Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption.
        Proc Natl Acad Sci U S A. 2007; 104: 11085-11090
        • Faroqui S.
        • Levi M.
        • Soleimani M.
        • Amlal H.
        Estrogen downregulates the proximal tubule type IIa sodium phosphate cotransporter causing phosphate wasting and hypophosphatemia.
        Kidney Int. 2008; 73: 1141-1150
        • Cirillo M.
        • Ciacci C.
        • De Santo N.G.
        Age, renal tubular phosphate reabsorption, and serum phosphate levels in adults.
        N Engl J Med. 2008; 359: 864-866
        • Ix J.H.
        • Chonchol M.
        • Laughlin G.A.
        • Shlipak M.G.
        • Whooley M.A.
        Relation of sex and estrogen therapy to serum fibroblast growth factor 23, serum phosphorus, and urine phosphorus: the Heart and Soul Study.
        Am J Kidney Dis. 2011; 58: 737-745